Featured Trial:
Lung Cancer Treatment

Featured Trial:
Colorectal Cancer Treatment

Featured Trial:
Melanoma Imaging

Featured Trial:
Head and Neck Cancer Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Member Blog

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

March 22, 2025

Categories

The March 2025 News from ECOG-ACRIN blog is now available

March 17, 2025

Categories

News Stories

Stem cell transplant may not be necessary in first remission for patients with mantle cell lymphoma and undetectable MRD (features EA4151)

March 5, 2025

Categories

News Stories

WATCH: Dr. Kathy Miller on how the PATINA trial (AFT-38/PrE0111) shifts the paradigm in HER2+/ER- breast cancer treatment

March 5, 2025

Categories

News Stories

LISTEN: A JAMA Network Learning podcast interview with Dr. Anand Jillella, author of the newly published results of study EA9131 in JAMA Oncology

February 25, 2025

Categories

News Stories

Top trial results of 2024: A year of significant advancements in cancer treatment by ECOG-ACRIN and PrECOG

February 25, 2025

Categories

The February 2025 News from ECOG-ACRIN blog is now available

Posts

ECOG-ACRIN Cancer Research Group Follow 7,815 6,306

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

; ECOG-ACRIN Cancer Research Group @eaonc ·

2h 1907086143973175684

In the #ComboMATCH Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with #cancer. Learn more: http://bit.ly/ComboMATCH #PrecisionMedicine #ClinicalTrial

Reply on Twitter 1907086143973175684 Retweet on Twitter 1907086143973175684 0 Like on Twitter 1907086143973175684 0 Twitter 1907086143973175684

; ECOG-ACRIN Cancer Research Group @eaonc ·

3h 1907070564872720585

Do you have #HER2positive #BreastCancer? If so, you may be eligible to participate in the phase 2 #ClinicalTrial EA1211/DIRECT, testing if FDG-PET/CT imaging can better predict a patient's response to treatment than the usual approach. Learn more: https://bit.ly/EA1211

Reply on Twitter 1907070564872720585 Retweet on Twitter 1907070564872720585 0 Like on Twitter 1907070564872720585 0 Twitter 1907070564872720585

Retweet on Twitter ECOG-ACRIN Cancer Research Group Retweeted

; PrECOG @PrECOGonc ·

22h 1906785434190885308

.@GBMCHealthcare is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in pts not in a #ClinicalTrial. Learn more:

Reply on Twitter 1906785434190885308 Retweet on Twitter 1906785434190885308 1 Like on Twitter 1906785434190885308 0 Twitter 1906785434190885308

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).